Navigation Links
In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells

Pre-Clinical Results Demonstrate Potential of ONCONASE for Treatment of Neuroblastoma

BLOOMFIELD, N.J., June 27, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that new data show ONCONASE, the company's lead drug candidate, is active against naive and chemoresistant neuroblastoma cells.

The pre-clinical in vitro and in vivo data published in Cancer Letters (2007; Vol. 250, Issue 1: 107-116) through a collaboration between Alfacell and Martin Michaelis, M.D., Ph.D., at the Institute of Medicinal Virology at Johann Wolfgang University of Frankfurt, were also recently presented in Germany.

Conclusions from the studies presented indicate that ONCONASE inhibits neuroblastoma cell growth and induces caspase-independent cell death in neuroblastoma cells independently of P-gp expression or p53 status, which has been shown to contribute to multi-drug resistance in neuroblastoma as well as most other human cancers. Transmission electronic microscope investigations suggest that ONCONASE induces a process in neuroblastoma cells called autophagy (the digestion of cellular constituents by enzymes of the same cell), which leads to apoptosis (programmed cell death). Anti-tumor activity of ONCONASE against drug-sensitive and chemoresistant neuroblastoma xenografts was confirmed in animals.

"The data speak to the broad potential application for ONCONASE in various types of cancer other than the gateway indication for mesothelioma," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "We now have an even better understanding of the mechanism of action that ONCONASE utilizes in overcoming multiple drug resistance in various tumor types."

Neuroblastoma is a cancer that forms in the nerve tissue. It is the most common cancer in infants, and the fourth most common type of cancer in children. Neurons (nerve cells) are the main components of the brain and spinal cord an d of the nerves that connect them to the rest of the body. Approximately one in 100,000 children develops neuroblastoma in the United States.


ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outc ome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                      Investor Contact:

    David Schull or Wendy Lau           Andreas Marathovouniotis

    Russo Partners                      Russo Partners

    212-845-4271                        212-845-4253


CONTACT: Media: David Schull, , or WendyLau, , +1-212-845-4271; Investors: AndreasMarathovouniotis, +1-212-845-4253, ,all of Russo Partners for Alfacell Corporation

Web site:

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
2. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants
6. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
7. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
8. Researchers Identify Intracellular Pathway of Alfacells Onconase
9. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
10. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
11. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... that they are handling security in light of the recent terrorist attacks in Paris, ... attempt to stop an attack from reaching U.S. soil. Especially around special events that ...
(Date:11/27/2015)... ... 2015 , ... A team of Swiss doctors has released a report on ... just posted the findings on the website. Click here to read the details ... mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the 106 ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component ... Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of ... distributed nationally, through a vast social media strategy and across a network of ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
Breaking Medicine News(10 mins):